Biotech Not Cratering, Just Deflating
To see where the biotech sector is headed tomorrow, it might be helpful for investors to look back, and more importantly, forget about, the recent past.
The outlook from this perspective is sobering: Biotech valuations are only now beginning to trade below historical levels, despite what seems like a calamitous drop in stock prices. Right, you guessed it: Biotechs could still head lower.
The Amex Biotechnology Index closed Wednesday at 309.32, quite an
accomplishment considering that a profit warning from drug-equipment maker
But don't call a bottom yet. The BTK has retrenched back to December 1999 levels, which is an interesting time frame because, as longtime biotech investors will recall, the sector, at this time, was in the midst of a bubble, inflated by the hype over genomics and, of course, the general mania in technology-related stocks. It may seem like a distant memory, but towards the end of 2000, the BTK actually approached 800. And as one reader points out, enthusiasm was so great that one analyst at Credit Suisse First Boston, in September 2000, was actually talking up the likelihood of BTK 1000.
Forget About ItWe bring this up to suggest that biotech investors might want to simply erase the roughly two-year biotech bubble from their memory, in order to better evaluate current valuations. That's what Lazard Freres biotech analyst Joel Sendek did recently, and it suggested to him that biotech valuations are only now beginning to trade below historical levels, despite the aforementioned steep slide in stock prices since late last year.
Take Genentech -- PleaseGenentech offers a good example of just how fragile biotech valuations are these days. The stock fell 5% to $28.70 Wednesday after Deutsche Bank Securities biotech analyst Dennis Harp used the day before the July 4th holiday to downgrade the company to market perform (read: hold) from buy. The main reason? Valuation. By Harp's calculation, Genentech was trading at a 2003 P/E-to-growth multiple of 1.5, a significant premium to the other profitable biotechs, which as a group, trade at a 2003 P/E-to-growth multiple of 0.8. Harp also believes that Genentech will come up short when it reports results later this summer from a Phase III trial of its experimental cancer drug, Avastin. His firm doesn't have a banking relationship with Genentech. Earnings season is typically a good time for biotech investors, but Biogen
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV